Changshan Biochemical Pharmaceutical (hereafter referred as CSBIO) was listed in Shenzhen Stock Exchange on 19 Aug. 2011, with registered capital of RMB110 million. Heparin Sodium BPC is the core product of CSBIO, of which market share ranks first in China. Its sales reached RMB410 million in 2010, accounting for 86.9% of CSBIO’s operating revenue. Through going public, CSBIO will expand its heparin sodium BPC capacity and realize an annual capacity of 3 trillion units.

For low molecular weight heparin calcium injection, CSBIO is one of the six enterprises that obtain production approval in China. Its market share topped the industry in China in 2009. When the fund-raise project reaches designed capacity, LMW heparin calcium injection capacity will be expanded from 4 million units to 20 million units, consequently, its sales will increase from RMB50 million in 2010 to be over RMB200 million.

Fund Raising Projects and Investment of Changshan Biochemical Pharmaceutical